Login
$ENGN
$1.95 +$0.06 (3.17%) After hours

Company Executives

Officer Age In this role 2025 pay Source
Ronald H.W. Cooper Also a director
Chief Executive Officer, President and Director
63 Not stated $5,758,289
Matthew Boyd
Chief Regulatory Officer
52 Since 2025
1 year
Not reported
Jill Buck
Chief Development Officer
52 Since 2025
1 year
Not reported
Anthony T. Cheung
Chief Scientific Officer
55 Since 2024
2 years
Not reported
Joan Connolly
Chief Technology Officer
57 Since 2024
2 years
Not reported
Lee G. Giguere
Chief Legal Officer and Corporate Secretary
46 Since 2024
2 years
Not reported
Alexander Nichols
Chief Strategy and Operations Officer
41 Since 2024
2 years
Not reported
Amy Pott
Chief Global Commercialization Officer
49 Since 2025
1 year
Not reported
Jason Duncan
Chief Legal & Admin Officer
Title from the Form 4 dated Nov 13, 2026
Not stated Not stated Not reported
William Grossman Also a director
Interim Chief Medical Officer
Title from the Form 4 dated Sep 22, 2026
Not stated Not stated Not reported
Constantine Chinoporos
Interim Chief Business Officer
Title from the Form 3 dated Jul 16, 2026
Not stated Not stated Not reported
Kathleen Richton
Senior Vice President, Finance
Title from the Form 8-K dated Jul 16, 2026
Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed May 8, 2026 · updated by the 8-K of Jul 16, 2026

Directors
8
serving now
Independent
7 of 8
stated in the proxy
Average tenure
1.9 years
from year joined
Director On board Independent Committees Other public boards 2025 pay Source
Ronald H.W. Cooper
2024
2 years
Not independent None stated C4 Therapeutics, Inc. Paid as CEO
Philip Astley-Sparke
2025
1 year
Independent
audit nominating and corporate governance
None stated $135,956
William Grossman
2025
1 year
Independent
research and development · Chair
None stated Not stated
Michael Heffernan
2025
1 year
Independent
audit compensation
Biohaven Ltd. $136,274
Gerald Brunk
2023
3 years
Independent
compensation · Chair research and development
None stated $121,601
Paul Hastings
2024
2 years
Independent
compensation nominating and corporate governance
Nkarta, Inc. $106,772
Wouter Joustra
2024
2 years
Independent
compensation
NewAmsterdam Pharma N.V., Vor Biopharma, Inc. $101,772
Lota Zoth
2023
3 years
Independent
audit · Chair nominating and corporate governance
Inovio Pharmaceuticals, Inc. $117,772

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

1 disclosed in the proxy filed May 8, 2026
each of its directors and certain of its executive officers
directors and certain executive officers of enGene
Amount not stated

Indemnification agreements requiring enGene to indemnify these individuals, and in certain cases their affiliates, and to advance expenses for proceedings.

With enGene Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support